Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Solriamfetol (Primary)
Indications Binge-eating disorder
Focus Registrational; Therapeutic Use
Acronyms ENGAGE

Most Recent Events

18 Feb 2025 According to a, Axsome Therapeutics media release, based on current enrollment trends, the Company now anticipates topline results from the ENGAGE Phase 3 trial in 2026.
06 May 2024 According to a, Axsome Therapeutics media release, company anticipates topline results from the ENGAGE study in 2025.
01 Apr 2024 According to a Axsome Therapeutics media release, the first patient was screened in the ENGAGE trial in March 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com